Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1861 to 1875 of 7615 results

  1. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 TS ID 11937

      Status ...

    Technology appraisal guidance
    Topic selection

  2. Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949

    Awaiting development [GID-TA11465] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer TS ID 11953

    Awaiting development [GID-TA11469] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Apremilast for treating moderate to severe plaque psoriasis in people aged 6 to 17 TS ID 11921

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]

    Awaiting development [GID-TA11162] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]

    Awaiting development [GID-TA10777] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Lonafarnib for treating progeria and progeroid laminopathies [ID3867]

      Status ...

    Highly specialised technologies guidance
    Topic selection

  8. Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]

    In development [GID-TA11410] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]

    Awaiting development [GID-TA11218] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]

    Awaiting development [GID-TA11100] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]

    Awaiting development [GID-TA11339] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Leriglitazone for treating andrenoleukodystrophy [ID3903]

    In development [GID-TA11445] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]

    Awaiting development [GID-TA11367] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]

    Awaiting development [GID-TA11406] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Melanoma (metastatic) - talimogene laherparepvec [ID508]

    In development [GID-TAG509] Expected publication date: 28 September 2016

    Technology appraisal guidance
    In development